BioTuesdays

Santhera inks exclusive distribution deal with Clinigen for AGAMREE in DMD

Santhera Pharmaceuticals Logo

Santhera Pharmaceuticals (SIX:SANN) and closely held Clinigen Group have announced the signing of a supply and distribution agreement that will make AGAMREE accessible to patients with Duchene muscular dystrophy (DMD) in countries where it is not currently commercially available from Santhera.

Santhera states that the agreement enables it to secure the majority share of revenue generated from product supply in these additional countries.

In a statement, Geert Jan can Daal, MD, Ph.D., CCO of Santhera, said, “This distribution agreement with Clinigen, which is complementary to other, earlier announced, partnerships and agreements, will allow Santhera to significantly increase our service level to patients and healthcare professionals through processing individual requests for AGAMREE from geographies in which Santhera is not directly represented or while negotiations with local partners are ongoing.”

Julie Gosper, SVP, Europe and partner markets at Clinigen, commented, “DMD is one of the most common and devastating types of muscular degeneration, it is a progressive condition diagnosed in childhood and it is encouraging to be able to help healthcare professionals support appropriate patients with an additional treatment option. We look forward to working with Santhera to make AGAMREE available to patients globally on an unlicensed basis in those territories where it is not currently licensed or reimbursed. This partnership demonstrates our ongoing commitment to accelerate access to medicines, to improve the quality of people’s lives around the world.”